Academic Content and Language Evaluation of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (6348)
All Articles published online
|
Publishing Process of This Article
|
Jan 7, 2014 (publication date) through Dec 20, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: |
Jia SW, Fu S, Wang F, Shao Q, Huang HB, Shao JY. |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v20/i1/183.htm |
| Number | Citing Articles |
| 1 |
Enrico Franceschi, Dario De Biase, Vincenzo Di Nunno, Annalisa Pession, Alicia Tosoni, Lidia Gatto, Giovanni Tallini, Michela Visani, Raffaele Lodi, Stefania Bartolini, Alba Ariela Brandes. The clinical and prognostic role of ALK in glioblastoma. Pathology - Research and Practice 2021; 221: 153447 doi: 10.1016/j.prp.2021.153447
|
| 2 |
JIANHUA LIU, HAOSHENG JIN, HONGXIA TIAN, GUODA LIAN, SHAOJIE CHEN, JIAYU LI, XUCHAO ZHANG, DONG MA. Anaplastic lymphoma kinase protein expression predicts micrometastases and prognosis for patients with hepatocellular carcinoma. Oncology Letters 2016; 11(1): 213 doi: 10.3892/ol.2015.3859
|
| 3 |
Anna Patrikidou, Isabelle Sinapi, Hélène Regnault, Florence Fayard, Mohamed Bouattour, Laetitia Fartoux, Sandrine Faivre, David Malka, Michel Ducreux, Valerie Boige. Gemcitabine and oxaliplatin chemotherapy for advanced hepatocellular carcinoma after failure of anti-angiogenic therapies. Investigational New Drugs 2014; 32(5): 1028 doi: 10.1007/s10637-014-0100-y
|
| 4 |
U. Peretti, R. Ferrara, S. Pilotto, S. Kinspergher, M. Caccese, A. Santo, M. Brunelli, A. Caliò, L. Carbognin, I. Sperduti, M. Garassino, M. Chilosi, A. Scarpa, G. Tortora, E. Bria. ALK gene copy number gains in non-small-cell lung cancer: prognostic impact and clinico-pathological correlations. Respiratory Research 2016; 17(1) doi: 10.1186/s12931-016-0422-8
|
| 5 |
Fang Wang, Thomas Bank, Gregory Malnassy, Maribel Arteaga, Na Shang, Annika Dalheim, Xianzhong Ding, Scott J. Cotler, Mitchell F. Denning, Michael I. Nishimura, Peter Breslin, Wei Qiu. Inhibition of insulin‐like growth factor 1 receptor enhances the efficacy of sorafenib in inhibiting hepatocellular carcinoma cell growth and survival. Hepatology Communications 2018; 2(6): 732 doi: 10.1002/hep4.1181
|
| 6 |
Rui Zhang, Xiaomei Gao, Jieliang Zuo, Beiyuan Hu, Jimeng Yang, Jing Zhao, Jinhong Chen. STMN1 upregulation mediates hepatocellular carcinoma and hepatic stellate cell crosstalk to aggravate cancer by triggering the MET pathway. Cancer Science 2020; 111(2): 406 doi: 10.1111/cas.14262
|
| 7 |
Tugce Baser, Ahmet Sureyya Rifaioglu, Mehmet Volkan Atalay, Rengul Cetin Atalay. Drug Repurposing Approach to Identify Candidate Drug Molecules for Hepatocellular Carcinoma. International Journal of Molecular Sciences 2024; 25(17): 9392 doi: 10.3390/ijms25179392
|
| 8 |
Bin Sun, Congli Hu, Zhibin Yang, Xiaofeng Zhang, Linlin Zhao, Junye Xiong, Junyong Ma, Lei Chen, Haihua Qian, Xiangji Luo, Lehua Shi, Jun Li, Xianshuo Cheng, Zhengfeng Yin. Midkine promotes hepatocellular carcinoma metastasis by elevating anoikis resistance of circulating tumor cells. Oncotarget 2017; 8(20): 32523 doi: 10.18632/oncotarget.15808
|
| 9 |
Jrhau Lung, Yu-Ching Lin, Ming-Szu Hung, Yuan Yuan Jiang, Kuan-Der Lee, Paul Yann Lin, Ying Huang Tsai. A sensitive and high throughput TaqMan-based reverse transcription quantitative polymerase chain reaction assay efficiently discriminates ALK rearrangement from overexpression for lung cancer FFPE specimens. Lung Cancer 2016; 94: 114 doi: 10.1016/j.lungcan.2016.02.004
|
| 10 |
Matthew G. Hanna, Vesna Najfeld, Hanna Y. Irie, Joseph Tripodi, Anupma Nayak. Analysis of ALK gene in 133 patients with breast cancer revealed polysomy of chromosome 2 and no ALK amplification. SpringerPlus 2015; 4(1) doi: 10.1186/s40064-015-1235-9
|
| 11 |
Suresh Bugide, Dhana Sekhar Reddy, Parmanand Malvi, Romi Gupta, Narendra Wajapeyee. ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models. iScience 2024; 27(5): 109800 doi: 10.1016/j.isci.2024.109800
|
| 12 |
Zhen Yu, Ronglei Zhao. Inhibition of anaplastic lymphoma kinase promotes apoptosis and suppresses proliferation in human hepatocellular carcinoma. Anti-Cancer Drugs 2018; 29(6): 513 doi: 10.1097/CAD.0000000000000616
|
| 13 |
Mengting Zhu, Valentina Rovella, Manuel Scimeca, Alessandro Mauriello, Yufang Shi, Julia Bischof, Jonathan Woodsmith, Alessandro Anselmo, Gerry Melino, Giuseppe Tisone, Massimiliano Agostini. Genomic and transcriptomic profiling of hepatocellular carcinoma reveals a rare molecular subtype. Discover Oncology 2024; 15(1) doi: 10.1007/s12672-023-00850-9
|
| 14 |
Federica Zito Marino, Gaetano Rocco, Alessandro Morabito, Chiara Mignogna, Martina Intartaglia, Giuseppina Liguori, Gerardo Botti, Renato Franco. A new look at the ALK gene in cancer: copy number gain and amplification. Expert Review of Anticancer Therapy 2016; 16(5): 493 doi: 10.1586/14737140.2016.1162098
|
| 15 |
Philipp Heumann, Andreas Albert, Karsten Gülow, Deniz Tümen, Martina Müller, Arne Kandulski. Insights in Molecular Therapies for Hepatocellular Carcinoma. Cancers 2024; 16(10): 1831 doi: 10.3390/cancers16101831
|